GLP-3R-(15mg)

GLP3R15 is an investigational synthetic peptide that acts as a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors to support weight loss and metabolic regulation.

Overview
GLP-3-R15, also known by its development code LY3437943, is a 39-amino acid synthetic peptide developed by Eli Lilly. It is designed to simultaneously activate three key receptors involved in metabolism: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG). This triple agonist mechanism distinguishes it from other peptides that typically target only one or two receptors, such as semaglutide (GLP-1) or tirzepatide (GLP-1/GIP).

Mechanism of Action
GLP-1 receptor activation: Enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.
GIP receptor activation: Supports insulin secretion and may improve fat metabolism.
Glucagon receptor activation: Increases energy expenditure and promotes fat oxidation.

By combining these effects, GLP3-R15 suppresses hunger, increases satiety, and boosts energy expenditure, potentially offering superior weight loss and glycemic control compared to single or dual receptor agonists.

Clinical Research and Efficacy
Phase 2 trials: Participants achieved up to 24.2% body weight loss at 48 weeks, with newer 68-week data showing 28.7% weight loss at the highest doses.

Phase 3 trials: Early results indicate significant reductions in body weight and improvements in metabolic markers, including A1C reductions of 1.7–2.0% in adults with overweight or obesity.

Status and Availability
GLP3-RT15 is not yet FDA-approved and is currently available only through clinical trials. Any products claiming to be retatrutide outside of these trials are considered illegal and unsafe. It is primarily being studied for obesity, metabolic disorders, and type 2 diabetes.

Key Points
GLP3-R15 is sometimes informally referred to as “GLP-3” due to its triple receptor activity.

It represents a next-generation peptide therapy in the incretin and metabolic research space.
Its unique triple agonist design may provide greater weight loss and metabolic benefits than existing GLP-1 or dual agonist therapies.

In summary, GLP3-R15 is a potent investigational peptide with a triple receptor mechanism, showing promising results for weight management and metabolic health, but it remains under clinical investigation and is not yet commercially available.

DISCLAIMER

EDUCATION PURPOSES ONLY. THIS INFORMATION IS IN NO WAY TO BE USED TO CURE, DIAGNOSE OR TREAT ANY CONDITION(S)